REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.81
-0.04 (-0.51%)
Jan 23, 2025, 12:19 PM EST - Market open
REGENXBIO Employees
REGENXBIO had 344 employees as of December 31, 2023. The number of employees decreased by 57 or -14.21% compared to the previous year.
Employees
344
Change (1Y)
-57
Growth (1Y)
-14.21%
Revenue / Employee
$245,137
Profits / Employee
-$694,201
Market Cap
386.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
RGNX News
- 7 days ago - Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 - Seeking Alpha
- 7 days ago - Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again - Seeking Alpha
- 9 days ago - REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - PRNewsWire
- 10 days ago - AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program - PRNewsWire
- 6 weeks ago - Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 - PRNewsWire
- 2 months ago - REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PRNewsWire
- 2 months ago - REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript - Seeking Alpha